| abstract |
A new class of nuclear receptor binding agents (NRBA) is provided. The present invention relates to a novel nuclear receptor binding agent (NRBA). NRBA includes inhibition and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress-related disorders such as Parkinson's disease and stroke, neurological diseases, eye disorders, cardiovascular disorders, and obesity Applicable to the inhibition and / or treatment of various diseases and symptoms. The NRBA of the present invention has antioxidant, anti-inflammatory, and anti-proliferative / differentiation promoting activities and may be a very effective chemopreventive agent for various age-related diseases. [Selection] Figure 1 |